Downloads
Press Release – 6 Nov 18 – Abzena announces 20m$ investment
Download the 6th November 2018 release.
DownloadEvents
References
News
Abzena announces location of new biologics GMP manufacturing site with up to 12 X 2000L bioreactors
Abzena is a Global Partner Research Organization (PRO) specializing in the integrated development and manufacture of[...] Read more
Sonnet BioTherapeutics selects Abzena as clinical stage manufacturing partner for its IL-12-FHAB cytokine-derived therapeutic candidate
PRINCETON, NJ and San Diego, CA, USA 22 October 2019 – Sonnet BioTherapeutics Inc., a clinical stage biopharmaceutical[...] Read more
Abzena announces 14-month cell line to phase 1 GMP service and appointment of Shahram Katousian as Head of biologics manufacturing
San Diego, USA, 3 June 2019 – Abzena, the leading biotherapeutics target to GMP partner research organization (PRO)[...] Read more
Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development
Cambridge, UK 21 March 2019 – Abzena, the leading biologics target to GMP partner research organisation (PRO),[...] Read more
Abzena and Lipum AB sign integrated CMC agreement to produce a novel biologic for autoimmune inflammatory diseases
San Diego, USA, 19 March 2019 – Abzena, the global biologics gene to GMP partner research organization, announced[...] Read more
ABZENA ANNOUNCES APPOINTMENT OF ELAINE SAPINOSO AS GLOBAL HEAD OF QUALITY
Addition of experienced leadership in GMP Quality as Abzena increases capacity in biologics and complex small molecule[...] Read more
Abzena Announces Expansion of Integrated Biologics Offering with the Addition of Preformulation and Formulation Capability
Dr. Jonathan Goldman, CEO, Abzena, announced that Abzena has augmented existing discovery to GMP drug substance and[...] Read more
Abzena announces 20m$ investment into expansion of integrated biotherapeutics offering (Biologics Drug Substance and ADC) and makes key executive appointment
Significant increase in capacity to 2000 L scale in new GMP facility, addition of extra cell line development capacity[...] Read more
Faron Pharmaceuticals Ltd announces that it has filed a Clinical Trial Application (CTA)
Faron Pharmaceuticals Ltd today announced that it has filed a Clinical Trial Application (CTA) for Clevegen®, an ABZENA[...] Read more
Abzena and Telix sign strategic manufacturing and bioconjugation agreement
Cambridge, UK and Melbourne, Australia, 2 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group[...] Read more
Abzena announces location of new biologics GMP manufacturing site with up to 12 X 2000L bioreactors
Abzena is a Global Partner Research Organization (PRO) specializing in the integrated development and manufacture of[...] Read more